EUCTR2008-000907-27-ES进行中（未招募）1 期
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Urothelial CancerEstudio multicéntrico, no comparativo, de Fase II en 2 etapas, para valorar la eficacia, seguridad y farmacocinética de AZD4877 administrado semanalmente en pacientes con cáncer de urotelio recurrente y avanzado
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of written informed consent
- •2.Male or female age =18 years
- •3.Histologically confirmed transitional cell carcinoma (TCC) of the urothelium (bladder, renal pelvis, ureter, or urethra). Mixed histology is allowed as long as the predominant histology is TCC
- •4.TNM Stage IV disease (see Appendix G) that is not amenable to curative surgery and/or radiotherapy
- •5.First recurrence after treatment with a maximum of two chemotherapeutic regimens, one of which must have been for unresectable and/or locally advanced disease, and the other of which must have been in either the adjuvant or neo-adjuvant setting.
- •6.Measurable disease per RECIST criteria (Appendix D). Previously irradiated lesions are not considered measurable
- •7.Eastern cooperation Oncology Group (ECOG) performance status of 0, 1, or 2 (Appendix C)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study treatment; 6 weeks if prior systemic mitomycin, nitrosourea, or suramin. One exception to this is palliative radiotherapy given (up to one week prior to study entry) for pain to non-target lesion bony metastases. Another exception to this is hormonal therapy for prostate cancer.
- •2.Inadequate bone marrow reserve as demonstrated by absolute neutrophil count (ANC) <1.5 x 109/L, platelet count (PLT) <100 x 109/L, or haemoglobin (Hgb) =9 g/L
- •3.Inadequate liver function as demonstrated by alanine amino transferase (ALT) or aspartate transaminase (AST) >2.5 x upper limit of normal (ULN); >5 x ULN in the presence of liver metastases
- •4.Impaired renal function, defined by creatinine >1.5 x ULN or creatinine clearance <40 mL/min, estimated by Cockcroft-Gault equation or measured via 24 h urine creatinine
- •5.Any evidence of severe or uncontrolled systemic diseases including known cases of Hepatitis B or C or human immunodeficiency virus (HIV). Screening for chronic conditions is not required, although patients known to have such conditions at screening should not be included
- •6.Unresolved toxicity greater than CTCAE grade 1 from previous anti-cancer therapy (excluding neurotoxicity or alopecia) or incomplete recovery or healing from previous surgery, unless agreed by AZ and the PI with documentation
- •7.Presence of currently active CNS involvement or clinical evidence of active CNS disease.
- •8.Patients with massive pleural effusions or ascites unless drained
- •9.Pregnancy or breast-feeding. Women of childbearing potential must have a negative pregnancy test prior to starting first dose of study treatment
- •10.Any severe concomitant condition which, in the opinion of the PI, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
- •11.Involvement in the planning and conduct of the study (applies to both AZ staff and study centre personnel)
- •12.Major surgery, in the opinion of the PI, within 4 weeks prior to first dose of study treatment
- •13.Incomplete healing from prior bladder surgery, biopsy, or exenteration, or if surgical revisions anticipated in next 2 months after study entry
- •14.Previous (within the last 5 years) or concurrent malignancies of other histologies, with the exception of cervical carcinoma in situ, adequately treated basal cell, squamous cell carcinoma of the skin, or prostate cancer
- •15.Use of any known significant modulators of CYP3A4 within 2 weeks of the first dose of AZD4877 and until Cycle 1, Day 8: Barbiturates including primidone, carbamazepine drugs including oxcarbazepine, clarithromycin, erythromycin, fluconazole, griseofulvin, hydantoins, itraconazole, ketoconazole, miconazole, nefazodone, rifampicin, troleandomycin, protease inhibitors, St. John’s wort, grapefruit juice and Seville orange juice (Preceding agents may be used after Cycle 1 Day 8 if deemed medically necessary by the PI and AZ)
- •16.Previous participation in any AZD4877 study
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Urothelial CancerStage IV urothelial CancerEUCTR2008-000907-27-GBAstraZeneca AB50
进行中（未招募）
不适用
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Urothelial CancerEUCTR2008-000907-27-DEAstraZeneca AB50
进行中（未招募）
1 期
A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - RAMSETEEUCTR2008-006182-88-DEovartis Pharma Services AG69
进行中（未招募）
不适用
A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - RAMSETEEUCTR2008-006182-88-NLovartis Pharma Services AG69
进行中（未招募）
1 期
A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in EuropeEUCTR2008-006182-88-SEovartis Pharma Services AG69